These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35457445)

  • 1. Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis.
    Sun Y; Zhu Z; Zhang J; Han P; Qi Y; Wang X; Yang L
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of medical insurance access negotiation on the utilization of innovative anticancer drugs in China: an interrupted time series analysis.
    Li C; Zhu J; Shan L; Zhou Y; Liu G; Zhu H; Wu Q; Cui Y; Kang Z
    BMC Health Serv Res; 2024 Jan; 24(1):90. PubMed ID: 38233857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
    Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
    Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study.
    Cai L; Tao T; Li H; Zhang Z; Zhang L; Li X
    J Glob Health; 2022 Dec; 12():11016. PubMed ID: 36527382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in anti-HER2 drugs consumption and influencing factors.
    Liu J; Zhang X; Wang B; Dai H; Dou D; Fang W
    Front Public Health; 2022; 10():944071. PubMed ID: 36159303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
    Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
    Front Public Health; 2022; 10():921093. PubMed ID: 35844892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
    Liu Y; Yi H; Fang K; Bao Y; Li X
    Front Public Health; 2022; 10():942638. PubMed ID: 35937254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
    Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
    BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
    Yang Y; Chen L; Ke X; Mao Z; Zheng B
    BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
    Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
    Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
    BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis.
    Qin Z; He M; Shen H; Liu S; Xu S; Chen L
    Front Public Health; 2024; 12():1381786. PubMed ID: 38903594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impacts of the National Medication Price-Negotiated Policy on the financial burden of cancer patients in Shandong province, China: an interrupted time series analysis.
    Ding Y; Zheng C; Wei X; Zhang Q; Sun Q
    BMC Public Health; 2022 Dec; 22(1):2363. PubMed ID: 36527037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation.
    Wu D; Xie J; Dai H; Fang W
    BMC Health Serv Res; 2022 Apr; 22(1):431. PubMed ID: 35365136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis.
    Zhang L; Wang X; Yao H; Ding B; Gao X; Li X
    Int J Equity Health; 2024 Jun; 23(1):116. PubMed ID: 38840134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J; Lan T; Lu H; Pan J
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.